You are here

Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R42HL122038-01A1
Agency Tracking Number: R42HL122038
Amount: $240,750.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
11452 El Camino Real Suite 120
San DIego, CA 92130-2080
United States
DUNS: 32635352
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 552-8585
Business Contact
Phone: (858) 461-1837
Research Institution
SAN DIEGO, CA 92161-0002
United States

 () -
 Domestic Nonprofit Research Organization

DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery, approaches that are cumbersome to apply. Consequently, we have considered the usefulness of a vector encoding a paracrine-type transgene. In this approach, the transgene acts as a hormone, having cardiac effects after being released to the circulation from a distant site. This approach would circumvent the problem of attaining high yield cardiac gene transfer and enable patients to be treated by a systemic injection during an office visit. Furthermore, the approach proposed would eliminate the need for intravenous delivery of therapeutic peptides and thereby circumvent repeated and prolonged hospital stays, high morbidity, and enormous economic costs. The most suited vector to achieve these goa

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government